Business Wire

Andersen Global styrker den juridiske kapacitet i Danmark

14.2.2025 15:49:00 CET | Business Wire | Pressemeddelelse

Del

Andersen Global styrker de juridiske kompetencer i Danmark gennem en samarbejdsaftale med Hansen TaxLegal, en international advokatvirksomhed med hovedsæde i København, der blandt andet fokuserer på velhavere.

Hansen TaxLegal består af erfarne fagfolk med årtiers erfaring inden for skatteregler og solid erfaring med det danske skattevæsen. Virksomheden betjener en bred kundekreds, herunder andre jurister, revisorer, velhavende kunder, kapitalfonde, virksomheder og aktionærer med primære aktier. Teamet, der konsekvent anerkendes af Chambers and Partners som en førende virksomhed, er specialister i udvikling af strategiske, kundecentrerede løsninger til formueforvaltning, civilret, planlægning af generationsskifte, fonde og trust, risikovurdering, transfer pricing, omstrukturering, køb & salg af virksomheder og skatterådgivning.

"Som en virksomhed, der vier sin arbejdsindsats til at levere resultater på højt niveau til vores kunder, fokuserer vi på at se løsninger, hvor andre ser udfordringer," siger Managing Partner Jan Hansen. "Vores team består af erfarne fagfolk med rødder i Andersen og »Big Four«, bringer et strategisk perspektiv til det enkelte kundeengagement, så vi effektivt kan opfylde kundernes mål. Samarbejdet med Andersen Global gør det muligt for os at udvide omfanget af vores tjenester og give vores kunder endnu mere værdi lokalt såvel som internationalt."

Mark Vorsatz, Andersen Globals Chairman og CEO, tilføjer: "Hansen TaxLegal nyder høj anseelse for deres solide lokalkendskab og urokkelige engagement i at skabe værdi for kunderne. Vi har opretholdt en gensidigt fordelagtig arbejdsrelation til Jan og hans team i årevis, hvilket gør dette samarbejde til det ideelle næste skridt. Deres ekspertise inden for velhaversegmentet og internationale skatteforhold placerer dem som en stærk udbygning af vores globale organisation, yderligere etablering af en problemfri, tværfaglig platform i regionen og styrkelse af vores evne til at imødekomme kundernes skiftende behov i Danmark og andre steder."

Andersen Global er en international sammenslutning af juridisk adskilte og uafhængige medlemsvirksomheder, der består af skattejurister samt skatte- og værdiansættelseseksperter i hele verden. Andersen Global, der blev etableret i 2013 af den amerikanske medlemsvirksomhed Andersen Tax LLC, har nu mere end 18.000 eksperter i hele verden og en tilstedeværelse på over 500 lokaliteter gennem sine medlemsvirksomheder og samarbejdsvirksomheder.

Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.

Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20250213945911/da/

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release

The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t

Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye